School of Dentistry, University of Granada, 18071 Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
Int J Mol Sci. 2023 Jul 25;24(15):11888. doi: 10.3390/ijms241511888.
The aim of this systematic review and meta-analysis was to evaluate the current evidence in relation to the clinicopathological and prognostic significance of epidermal growth factor receptor (EGFR) overexpression in patients with oral squamous cell carcinoma (OSCC). We searched MEDLINE/PubMed, Embase, Web of Science, and Scopus for studies published before November 2022. We evaluated the quality of primary-level studies using the QUIPS tool, conducted meta-analyses, examined inter-study heterogeneity via subgroup analyses and meta-regressions, and performed small-study effects analyses. Fifty primary-level studies (4631 patients) met the inclusion criteria. EGFR overexpression was significantly associated with poor overall survival (hazard ratio [HR] = 1.38, 95% confidence intervals [CI] = 1.06-1.79, = 0.02), N+ status (odds ratio [OR] = 1.37, 95%CI = 1.01-1.86, = 0.04), and moderately-poorly differentiated OSCC (OR = 1.43, 95% CI = 1.05-1.94, = 0.02). In addition, better results were obtained by the application of a cutoff point ≥10% tumor cells with EGFR overexpression ( < 0.001). In conclusion, our systematic review and meta-analysis supports that the immunohistochemical assessment of EGFR overexpression may be useful as a prognostic biomarker for OSCC.
本系统评价和荟萃分析的目的是评估目前关于表皮生长因子受体 (EGFR) 过表达与口腔鳞状细胞癌 (OSCC) 患者临床病理和预后意义的证据。我们在 MEDLINE/PubMed、Embase、Web of Science 和 Scopus 中搜索了截至 2022 年 11 月发表的研究。我们使用 QUIPS 工具评估了初级研究的质量，进行了荟萃分析，通过亚组分析和荟萃回归检查了研究间异质性，并进行了小研究效应分析。符合纳入标准的有 50 项初级研究（4631 名患者）。EGFR 过表达与总生存期不良显著相关（风险比 [HR] = 1.38，95%置信区间 [CI] = 1.06-1.79， = 0.02）、N+状态（比值比 [OR] = 1.37，95%CI = 1.01-1.86， = 0.04）和中低分化 OSCC（OR = 1.43，95%CI = 1.05-1.94， = 0.02）。此外，通过应用 EGFR 过表达≥10%肿瘤细胞的截断值（ < 0.001）可获得更好的结果。总之，本系统评价和荟萃分析支持免疫组织化学评估 EGFR 过表达可能是 OSCC 的一种有用的预后生物标志物。
